National Cancer Institute, Research Contracts Branch, TCS, 6120 Executive Blvd, Room 603, MSC 7220, Bethesda Md 20892-7220

A -- DETAILED DRUG EVALUATION AND DEVELOPMENT OF TREATMENT STRATEGIES FOR CHEMOTHERAPEUTIC AGENTS SOL N01-CM-57207 POC Carolyn E. Barker, Contract Specialist, 301/496-8620 or Therese M. Dick, Contracting Officer, 301/496-8620 E-MAIL: Carolyn E. Barker, barkerc@rcb.nci.nih.gov. The Biological Testing Branch of the Development Therapeutics Program, Division of Cancer Treatment, Diagnosis, and Centers, National Cancer Institute (NCI), National Institutes of Health (NIH), is planning to negotiate with Southern Research Institute for additional work and effort required under Contract N01-CM-57207. This contract was awarded in the amount of $2,081,346 for a 3-year base period of 02/16/95 -- 02/15/98 with options to extend the performance period through 02/15/99 (Option I for $760,795) and through 02/15/00 (Option II for $796,662), for a total 5-year contract amount of $3,638,803. The annual level of effort required for contract performance was 12,160 direct labor hours/year. This project is for the evaluation of compounds for anti-cancer activity in experimental in vivo tumor models. Contract studies focus on agents identified by the disease-oriented drug screen. Southern Research Institute performs extensive schedule dependency studies to maximize the effectiveness of selectedagents which are to be evaluated in clinical trials. As requested by NCI, the Contractor also performs 2-way drug combination and 3-way drug combination studies which are more expensive to perform than studies with single agents. Additional contract requirements and effort have become necessary because of a larger than anticipated demand for combination drug studies with an urgent time frame requirement due to clinical requirements. The urgency of establishing clinical trials based upon testing in objective pre-clinical models requires that testing be performed within a very limited time-frame. Considerable time is required to actually test various relevant combinations of regimens. Southern Research Institute has a unique capability because they not only established the tumor models required for study, but also because they keep the calibrated tumor material in constant supply. NCI cannot afford to wait for appropriate models to be established by another organization. Competition is also not considered practical because any other organization would need to expend considerable time and cost to develop the biological "reagents" required for these studies. Authority: 41 USC 253(c)(1), FAR 6.302-1(a)(2). Collect calls will not be accepted. Se numbered Note 22. (0265)

Loren Data Corp. http://www.ld.com (SYN# 0001 19970925\A-0001.SOL)